[A18-40] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Last updated 17.09.2018

Project no.:
A18-40

Commission:
Commission awarded on 15.06.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Treatment-naive adults with advanced (unresectable or metastatic) melanoma with BRAF V600 WT tumour

Result of dossier assessment:

Due to disadvantages in health-related quality of life and side effects, indication of lesser benefit in comparison with the appropriate comparator therapy (nivolomab alone)

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Project no. Title Status
A19-11 Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A15-50 Nivolumab - Addendum to Commission A15-27 Commission completed
A16-76 Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A16-57 Nivolumab (NSCLC) - Addendum to Commission A16-25 Commission completed
A16-56 Nivolumab (renal cell carcinoma) - Addendum to Commission A16-24 Commission completed
A17-54 Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24 Commission completed
A18-53 Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A16-25 Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V Commission completed
G17-10 Nivolumab Squamous cell carcinoma of the head and neck - Addendum to A17-24 Commission completed
A16-24 Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V Commission completed
A15-32 Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) Commission completed
A15-27 Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment) Commission completed
A17-27 Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Commission completed
A17-24 Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V Commission completed
A16-35 Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-29 Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A16-68 Nivolumab (melanoma) - Addendum to Commission A16-35 Commission completed
A17-21 Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76 Commission completed
A15-58 Nivolumab - Addendum to Commission A15-32 Commission completed
A20-121 Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-118 Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-39 Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Commission completed
A21-59 Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Commission work started

Federal Joint Committee (G-BA)

2018-12-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.